Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
April 27 2021 - 3:35PM
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines
company creating a new class of non-viral gene therapy, today
announced three digital presentations at the American Society of
Gene & Cell Therapy (ASGCT) 2021 Virtual Annual Meeting taking
place May 11-14. The presentations will cover data supporting use
of the company’s platform for antibody gene therapy, a summary of
previously released preclinical data from the hemophilia A program
and insight into ceDNA construct engineering for factor VIII.
“We look forward to sharing preclinical data supporting the
broad potential of our platform in antibody gene therapy and to
providing an overview of our lead hemophilia A program,” said
Matthew Stanton, Ph.D., chief scientific officer of Generation Bio.
“The hemophilia A program is on track and we continue to expect
additional non-human primate data by mid-year.”
Digital presentations will be available online to registered
attendees beginning May 11.
Generation Bio will present:
- Vector Optimization for Non-Viral Antibody Gene Therapy
and Expression of Human Monoclonal Antibodies in
Mice
- Non-Viral Gene Delivery of Human FVIII to Hemophilia A
Mice and Non-Human Primates
- When Size Matters: FVIII Construct Optimization
Leveraging ceDNA, a Non-Viral Gene Therapy Platform
About Generation Bio
Generation Bio is an innovative genetic medicines company
focused on creating a new class of non-viral gene therapy to
provide durable, redosable treatments for people living with rare
and prevalent diseases. The company’s non-viral platform
incorporates a proprietary, high-capacity DNA construct called
closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle
delivery system, or ctLNP; and an established, scalable capsid-free
manufacturing process. The platform is designed to enable
multi-year durability from a single dose of ceDNA and to allow
titration and redosing if needed. The ctLNP is designed to deliver
large genetic payloads, including multiple genes, to specific
tissues to address a wide range of indications. The company’s
efficient, scalable manufacturing process supports Generation Bio’s
mission to extend the reach of gene therapy to more people, living
with more diseases, in more places around the world.
For more information, please visit www.generationbio.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the company, including statements about our
strategic plans or objectives, our technology platforms, our
research and clinical development plans, and other statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important
factors, including: uncertainties inherent in the identification
and development of product candidates, including the conduct of
research activities, the initiation and completion of preclinical
studies and clinical trials and clinical development of the
company’s product candidates; uncertainties as to the availability
and timing of results from preclinical studies and clinical trials;
whether results from preclinical studies will be predictive of the
results of later preclinical studies and clinical trials;
expectations for regulatory approvals to conduct trials or to
market products; challenges in the manufacture of genetic medicine
products; whether the company’s cash resources are sufficient to
fund the company’s operating expenses and capital expenditure
requirements for the period anticipated; the impact of the COVID-19
pandemic on the company’s business and operations; as well as the
other risks and uncertainties set forth in the “Risk Factors”
section of our most recent annual report on Form 10-K, which is on
file with the Securities and Exchange Commission, and in subsequent
filings the company may make with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent the company’s views as of the date
hereof. The company anticipates that subsequent events and
developments will cause the company’s views to change. However,
while the company may elect to update these forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the company’s views as of
any date subsequent to the date on which they were made.
Contacts:
InvestorsMaren KillackeyGeneration
Bio541-646-2420mkillackey@generationbio.com
MediaAlicia WebbGeneration
Bio847-254-4275awebb@generationbio.com
Stephanie SimonTen Bridge
Communications617-581-9333stephanie@tenbridgecommunications.com
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From May 2023 to May 2024